1. Home
  2. PRPO vs XLO Comparison

PRPO vs XLO Comparison

Compare PRPO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$26.97

Market Cap

44.4M

Sector

Industrials

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$8.41

Market Cap

39.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRPO
XLO
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
39.4M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
PRPO
XLO
Price
$26.97
$8.41
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
8.9K
319.7K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
35.03
60.79
EPS
N/A
N/A
Revenue
$18,532,000.00
$6,344,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
21.95
N/A
52 Week Low
$4.90
$0.46
52 Week High
$29.53
$8.09

Technical Indicators

Market Signals
Indicator
PRPO
XLO
Relative Strength Index (RSI) 53.64 92.44
Support Level $22.58 $0.63
Resistance Level $28.76 N/A
Average True Range (ATR) 1.36 0.38
MACD -0.09 0.72
Stochastic Oscillator 46.83 97.01

Price Performance

Historical Comparison
PRPO
XLO

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: